EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

Samuel Margolis, Andre Naguib Guirguis, Catherine Lee, Saiya Smith, Alexis LeVee, Marla D Lipsyc-Sharf, Aditya Bardia, Mina S Sedrak iD

Breast Cancer Research and Treatment · 2026

DOI: 10.1007/s10549-026-08051-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Samuel Margolis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Breast Neoplasms, Drug Approval, Antineoplastic Agents. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH, Breast Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Patient-reported outcomes (PROs) inform benefit-risk tradeoffs in breast cancer treatment, yet reporting quality across registration trials remains incompletely characterized.

Methods

We conducted a scoping review of PRO reporting in randomized trials supporting FDA breast cancer drug approvals (January 2011–December 2024), identified via the FDA Oncology Approval Notifications database. Associated manuscripts were retrieved through systematic PubMed and EBSCO searches using trial-specific NCT identifiers. We assessed PRO endpoint prespecification status, instruments used, PRO publication delay (defined as the interval in months between the primary trial manuscript and corresponding PRO-dedicated manuscript publication date), and missing data reporting across eligible primary trial, PRO-dedicated, and subpopulation-specific PRO manuscripts.

Results

We identified 34 FDA breast cancer drug approvals supported by 36 unique randomized trials, yielding 45 eligible manuscripts. No trial designated PROs as a primary or co-primary endpoint; nine (25%) did not explicitly prespecify them. Median PRO publication delay was 18 months, with eight trials experiencing a delay of two or more years. Missing data handling methods were described in 33% of manuscripts and reasons for missingness in 11%.

Conclusion

In this scoping review, PROs were commonly collected but inconsistently prespecified, often delayed, and incompletely reported. Registration trials should strengthen PRO prespecification, reduce publication delay, and adhere to missing data reporting standards. Clinical trial number Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresBreast NeoplasmsDrug ApprovalAntineoplastic AgentsHumansFemaleUnited StatesRandomized Controlled Trials as TopicClinical Trials as TopicUnited States Food and Drug Administration

Stichwörter der Autor:innen

Breast cancerClinical trialsDrug approvalPatient-reported outcomesQuality of lifeRegulatory scienceTolerabilityToxicity

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicine, University of California, Los Angeles, CA, USA.
  • Department of Medicine, University of California, Los Angeles, CA, USA. msedrak@mednet.ucla.edu.
  • David Geffen School of Medicine at UCLA, 650 Charles Young Drive South, Room A2-125 CHS, Los Angeles, CA, 90095-6900, USA. msedrak@mednet.ucla.edu.

ORCID-Profile: Mina S Sedrak

Förderung

  • NIA NIH HHS
  • NIH
  • Breast Cancer Research Foundation

Zitieren

APA

Margolis, S., Guirguis, A. N., Lee, C., Smith, S., LeVee, A., Lipsyc-Sharf, M. D., Bardia, A., & Sedrak, M. S. (2026). Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08051-y

Vancouver

Margolis S, Guirguis AN, Lee C, Smith S, LeVee A, Lipsyc-Sharf MD, et al. Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08051-y

BibTeX
@article{Margolis2026,
  author = {Margolis, Samuel and Guirguis, Andre Naguib and Lee, Catherine and Smith, Saiya and LeVee, Alexis and Lipsyc-Sharf, Marla D and Bardia, Aditya and Sedrak, Mina S},
  title = {Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  doi = {10.1007/s10549-026-08051-y}
}
Kostenlos starten →